Clinical Trial Update: Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the long-term safety of the combined inhaler QVA149A compared with placebo and standard of care in chronic obstructive pulmonary diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QVA149A

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2016-06-15